Form 4: Exelixis Director Receives Equity Grant

Director Stelios Papadopoulos was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Summary

• Director Stelios Papadopoulos acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership for the director following this transaction is 1,197,595 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the Reporting Person's continuous service through May 27, 2027.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant follows standard equity incentive plan structures common among mid-cap biotechnology firms.
• The vesting period of one year is consistent with typical director compensation cycles for companies of similar market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation